# Nitric Oxide and Low-Density Lipoprotein Oxidation

NEIL HOGG \* and B. KALYANARAMAN

*Biophysics Research Institute, Medical College* of *Wisconsin, 8701 Watertown Plank Road, Milwaukee,* Wl *53226, USA* 

Accepted by Prof. V. Darley-Usmar

*(Received 13 December 1997; In revised* form *16 Junuay 1998)* 

Nitric oxide can have both pro-oxidant and antioxidant effects on low-density lipoprotein. Nitric oxide does not appear to react directly with components of LDL. However, in the presence of oxygen (through NO<sub>2</sub> and  $N_2O_3$  formation) or superoxide (through peroxynitrite formation) nitric oxide may cause oxidation of the lipid, protein and antioxidant components of LDL. Conversely, nitric oxide is a potent inhibitor of LDL oxidation when initiated by copper ions or by azo-initiators. The possible implications of these observations to vascular pathology are discussed.

#### **INTRODUCTION**

The comprehensive and continuing investigation of low-density lipoprotein (LDL) oxidation has provided an invaluable insight into the mechanistic complexity **of** the lipid peroxidation chain reaction in a multi-component biological sys $tem.$ <sup>[1-4]</sup> The oxidation of LDL has been extensively studied, mainly because of the potential importance of this process in the early stages of atherosclerosis.<sup>[5,6]</sup> In addition to this, LDL represents a useful model in which to examine, at the molecular level, oxidative and antioxidant

processes. LDL is a complex particle that consists of a phospholipid outer monolayer that enspheres a cholesterol-ester core.<sup>[1]</sup> A single molecule of apolipoprotein B (apo-B) is integrated into this lipid droplet, and has structural, recognition, and enzymatic activities. $[17,8]$  In addition, LDL contains numerous lipid-soluble molecules, including vitamin E, ubiquinol and  $\beta$ -carotene, which have variable antioxidant properties. $[1]$ This particle is therefore a self-contained model for the study of lipid-protein-antioxidant reactions with respect to lipid peroxidation.

Nitric oxide is an important regulator of vascular diseases. Inhibition of endothelial nitric oxide synthase (NOS) enhances atherosclero $sis,$ <sup>[9,10]</sup> and arginine supplementation inhibits and regresses atherosclerosis, $^{[11]}$  presumably by enhancing NO formation. Paradoxically, atherosclerotic tissue generates more oxides of nitrogen than healthy tissue.  $\left[12\right]$  This suggests that although nitric oxide synthase activity is upregulated in atherosclerotic tissue, nitric oxide is being oxidized before it can exert its beneficial, anti-atherogenic effects. The most rapid, and most likely, scavenger **of** nitric oxide is



<sup>\*</sup>Corresponding **author.** 

superoxide, $^{[13-15]}$  which has been shown to be elevated in atherosclerotic tissue.<sup>[15]</sup> Nitric oxide reacts with superoxide at a diffusion-controlled rate to generate peroxynitrite (Eq.  $(1)$ ):<sup>[13,16]</sup>

$$
\bullet\,\text{NO} + \text{O}_2^-\bullet\,\longrightarrow\,\text{ONOO}^-\qquad\qquad(1)
$$

This review will examine the direct effects of nitric oxide and its oxidation products on LDL from the perspective of both oxidative chemistry and vascular pathology.

### **THE REACTIONS OF NITRIC OXIDE WITH COMPONENTS OF THE LDL PARTICLE**

Nitric oxide has been reported to have multiple effects on LDL or on isolated components of the LDL particle. Wang *et al.*<sup>[17]</sup> showed evidence that nitric oxide could directly oxidize LDL lipid and fragment apo-B. Such changes were accompanied by a change in electrophoretic mobility consistent with lipid oxidation. These investigators used dissolved nitric oxide gas  $(125-500 \,\mu M)$  added, under anaerobic conditions, in a single addition or in aliquots over time. In agreement with this report, Chang *et al.*<sup>[18]</sup> demonstrated that bubbling nitric oxide gas through a solution of LDL, for **3** min, followed by 7 days incubation causes a reduction in LDL  $\beta$ -carotene content.

In contrast to these studies are several reports that show little, if any, oxidative activity of nitric oxide. Darley-Usmar *et al.*<sup>[19]</sup> showed that incubation of LDL with the nitric oxide donor S-nitroso-N-acetyl penicillamine (SNAP) did not result in an alteration in electrophoretic mobility. In addition Jessup *et al.*<sup>[20]</sup> demonstrated only the ubiquinone content of LDL is significantly diminished by addition of up to 200 **pM** solutions of nitric oxide and only above  $100 \mu M$  nitric oxide was a small increase in lipid hydroperoxide observed.

Goss *et al.*<sup>[21]</sup> attempted to reconcile these discrepancies by demonstrating that bolus addition of NO  $(500 \,\mu\text{M})$  to LDL under aerobic conditions can cause a mild oxidation that is enhanced by contaminating transition metal ions in the medium. **In** the presence of the transition metal ion chelator DTPA the enhancement is not observed. Under strict anaerobic conditions nitric oxide does not oxidize LDL lipid, and oxidation is likely due to nitrogen dioxide and dinitrogen tetraoxide. It has previously been shown that nitrogen dioxide will oxidize unsaturated fatty acids.<sup>[22]</sup>

Reports that nitric oxide can directly react with isolated components of the LDL particle<sup>[23]</sup> are also likely due to the oxidative chemistry of nitrogen dioxide. For example,  $\alpha$ -tocopherol is not oxidized by nitric oxide, but is oxidized to the quinone by nitrogen dioxide.<sup>[24]</sup> Interestingly, an apparently direct reaction between  $\beta$ -carotene and nitric oxide has been demonstrated to form a nitroxide by addition **of** nitric oxide to the conjugated diene moiety.<sup>[25]</sup> However, nitric oxide, when slowly released into solution does not result in significant oxidation of  $\beta$ -carotene.<sup>[21]</sup>

#### **REACTIONS OF PEROXYNITRITE WITH LDL**

The first reports demonstrating an oxidative reaction of peroxynitrite towards LDL **used**  the sydnonimine  $SIN-1$ .<sup>[19,20]</sup> This compound simultaneously releases nitric oxide and superoxide, which rapidly react to form peroxynitrite.<sup>[26,27]</sup> Incubation of LDL with SIN-1, resulted in the depletion of LDL antioxidants and the formation of both lipid hydroperoxides and thiobarbituric acid reactive substances (TBARS), indicating lipid peroxidation was occurring.<sup>[19]</sup> In addition, SIN-1 decreased the concentration of free amino groups of apo-B and increased the net negative charge of the lipoprotein.<sup>[19]</sup> These changes are similar to those observed when LDL is oxidized by  $copper(II)$  ions.

Later studies using chemically synthesized peroxynitrite indicated that peroxynitrite-treated LDL is a scavenger for the macrophage scavenger receptor and is therefore potentially atherogenic.<sup>[28]</sup> One of the earliest reactions to occur during the oxidation of LDL by SIN-1 is the oxidation of  $\alpha$ -tocopherol to  $\alpha$ -tocopheryl quinone.[291 This reaction also occurs in rat liver microsomes<sup>[30]</sup> and in organic solution.<sup>[31]</sup> The mechanism of reaction appears to be a direct two-electron oxidation of a-tocopherol to the *a*tocopheryl cation, followed by nucleophillic addition of OH<sup>-</sup> to the 8a position.<sup>[31]</sup>  $\gamma$ -tocopherol, a minor component of vitamin E, reacts with peroxynitrite to form a nitrated product (4-nitro - $\gamma$ -tocopherol) and the orthoquinone, tocored.<sup>[32,33]</sup> The difference in chemistry between  $\alpha$ - and  $\gamma$ -tocopherol is related to the absence of a **methylgroupatthe4positionofy-tocopherol.More**  recently, peroxynitrite has been shown to oxidize apo-B cysteinyl thiols by a lipid peroxidationdependent pathway.<sup>[34]</sup>

## **INHIBITION OF LDL OXIDATION BY NITRIC OXIDE**

The oxidative modification of LDL is thought to be a critical step in the formation of an atherosclerotic lesion.<sup>[5]</sup> It is hypothesized that LDL that migrates to the arterial intima is subject to an oxidative stress. This causes oxidation of LDL lipid, which ultimately results in a decrease in net negative charge of apo-B. Once apo-B is modified, LDL is taken up by interstitial macrophages, via the scavenger receptor, to form the foam cells that are characteristic of early lesion development. The subendothelial environment is constantly exposed to nitric oxide from the basal activity of endothelial nitric oxide synthase. Consequently any interactions between nitric oxide and LDL may have profound importance to the biological chemistry of this lipoprotein.

The first suggestions that nitric oxide might inhibit LDL oxidation came from two reports<sup>[20,35]</sup> that endotoxin-stimulated macrophages were less able to oxidize LDL than unstimulated cells. Endotoxin induces the synthesis of nitric oxide

synthase, leading to enhanced nitric oxide production.[361 In addition, the attenuated ability of endotoxin-stimulated macrophages to oxidize LDL was reversed by L-N-monomethyl arginine, a specific inhibitor of NOS. There are several chemical models for the oxidative modification of LDL. The two most commonly employed use either a copper(I1) salt or an 'azo-initiator' to initiate lipid oxidation. One fundamental difference between these two methods is that initiation of oxidation by copper(I1)-dependent is autocatalytic whereas initiation by azo-initiators is effectively linear. The mechanisms by which these oxidants initiate lipid peroxidation are shown in Scheme 1.

Catalytic quantities of copper(I1) ions will oxidize LDL lipid with characteristic kinetics (Figure **lp3']** The change in absorbance at **234** nm is an easy, and continuous, way to monitor the oxidation process. The absorbance change arises from the rearrangement of the fatty acid double



SCHEME **1** *Initiation* of *lipid peroxidation by copper ions and ABAP.* **ABAP** decays to give a peroxyl radical **(ABAP-OO\*)**  which can abstract a hydrogen atom from an unsaturated lipid **(LH)** to **give** a lipid radical (L=). This radical feeds into the lipid peroxidation chain reaction. Copper ions react with lipid hydroperoxide to generate lipid peroxyl and alkoxyl radicals that can also feed into the peroxidation chain reaction. Copper-dependent oxidation is auto-catalytic as lipid hydroperoxide, the product of lipid peroxidation, feeds back to copper and re-initiates a chain of oxidation.

bond arrangement, from a non-conjugated diene to a conjugated diene, that occurs during lipid peroxidation (Scheme 2). The kinetic profile of conjugated diene formation can be divided into three regions (Figure **l).'37]** During the first period, referred to as the lag period, a low level of oxidation occurs. The lag **time** is due both to the endogenous antioxidants, which are consumed during this period, and to the autocatalytic nature of the reaction. Following the lag period, oxidation accelerates to reach a rapid and fairly linear rate, in what is often called the propagation phase. The maximum rate of the



FIGURE **1** *Kinetics* of *LDL oxidation in the presence* of *different classes* of *inhibitors.* **The kinetics** of **copper-dependent**  LDL **oxidation was modeled** using **kinetic simulation software** (see **Ref. I211 for details). Simulations were performed in the presence** of **increasing concentrations** of **four different classes of antioxidant: (A) a metal ion chelator,** *(8)* **a hydrogen donator,** (C) **a peroxyl radical scavenger and** (D) **nitric oxide.** 



*SCHEME* **2 Conjugated diene formation during lipid peroxidation.** 

propagation phase occurs when the rate of initiation equals the rate of termination. **The** end of the propagation phase occurs as a result of depletion of either substrate or oxygen, and is followed by a complex third phase. During this last phase, lipid hydroperoxides are broken down to a complex mixture of products including aldehydes and hydrocarbons.<sup>[38]</sup>

Copper-dependent lipid peroxidation is thought to proceed through the reactions shown in Eqs. (2)-(6). Redox cycling of copper ions results in the

ults in the  
Cu<sup>2+</sup> + LOOH 
$$
\longrightarrow
$$
 Cu<sup>+</sup> + LOO $\bullet$  + H<sup>+</sup> (2)

$$
Cu^{+} + LOOH \longrightarrow Cu^{2+} + LO\cdot + OH^{-} \quad (3)
$$

$$
u^{+} + LOOH \rightarrow Cu^{2+} + LO \rightarrow OH^{-}
$$
 (2)  
LOO $\bullet$  + LH  $\rightarrow$  LOOH + L $\bullet$  (4)

$$
O\bullet + LH \longrightarrow LOOH + L\bullet \tag{4}
$$
  
\n
$$
L\bullet + O_2 \longrightarrow LOO\bullet \tag{5}
$$

$$
2L\bullet/LOO\bullet \longrightarrow Products \qquad (6)
$$

decomposition of lipid hydroperoxides (low levels of which are always present in **LDL)** to form lipid alkoxyl and peroxyl radicals (Eqs. (2) and *(3))* which both feed into the lipid peroxidation chain reaction (Eqs. **(4)** and (5)). In the absence of antioxidants, chain termination *oc*curs through radical-radical reactions (Eq. **(6)).** 

Jnhibitors of lipid peroxidation affect the shape of the conjugated diene

$$
LOO\bullet + AH \longrightarrow LOOH + A\bullet \qquad (7)
$$

curve (Figure 1).<sup>[39,40]</sup> Inhibitors can be divided into three main classes: **(i)** copper chelators, **(ii)**  hydrogen atom donors and (iii) peroxyl radical scavengers. As shown in Figure lA, antioxidants that work through copper chelation, such as EDTA, cause an increase in the length of the lag period of oxidation and a decrease in the rate of oxidation during the propagation phase. The plot **of** lag time vs. concentration for a copper chelator is shown in Figure 2. As the concentration of free copper approaches zero, the lag period approaches **infinity.** Figure **1B** shows the typical effect of hydrogen donators (AH), **such** as  $\alpha$ -tocopherol on conjugated diene formation.

For personal use only.

**Cu Chelator H** Donator Lag Time Nitric Oxide Peroxyl Scavenger Antioxidant Concentration

FIGURE *2 Effect of different classes of antioxidant on the* **lag**  *time of LDL oxidation.* **Lag times, calculated** from **Figure 1, were plotted as a function of antioxidant concentration for the four classes of antioxidant.** 

These compounds donate a hydrogen atom to the peroxyl radical thus breaking the chain of propagation **(Eq.** (7)). As the net change in lipid peroxide, due to this reaction, is zero once the antioxidant has been consumed oxidation proceeds as before. Consequently the length of the lag time is a linear function of antioxidant concentration (Figure 2). Variations from this ideal situation can occur if the antioxidant radical has a low ability to initiate peroxidation reaction, as has been suggested for  $\alpha$ -tocopherol.<sup>[3]</sup>

Peroxyl radical scavengers act by reacting with and removing peroxyl radicals (Eq. (8)). This type of activity is most likely an attribute of<br>
LOO $\cdot + A \cdot \longrightarrow$  LOOA (8)

$$
LOO\bullet + A\bullet \longrightarrow LOOA \tag{8}
$$

stable free radicals. The  $\alpha$ -tocopheroxyl radical, generated from hydrogen donation reactions (Eq. *(7)),* has been suggested to be a peroxyl radical scavenger, consequently each  $\alpha$ -tocopherol molecule inhibits two chains of oxidation.<sup>[41]</sup> As true peroxyl radical scavengers do not regenerate lipid peroxide (cf Eqs. (7) and (8)), the inhibition profile for these compounds is expected to be that in Figure 1C. The non-linear dependence of the lag-time on the antioxidant concentration (Figure 2) arises from the fact that the hydroperoxide concentration is reduced during this time. Consequently, LDL becomes more resistant to oxidation by copper during the **lag**  time.

Nitric oxide reacts with peroxyl radicals at near diffusion controlled rates $A^{42}$  and is therefore likely to act as a peroxyl radical scavenger (Eq. (8)). However, a study of lag-time vs. nitric oxide donor concentration gives the profile shown in Figure 1D.<sup>[21]</sup> Although at low concentrations nitric oxide appears to act as a peroxyl radical scavenger, higher concentrations of nitric oxide are less effective than would be expected, giving a sigmoidal dependence (Figure 2). This can be explained if it is assumed that the product of the antioxidant reaction (putatively LOO-**NO[431)** is unstable and slowly decays **to** a hydroperoxide or a peroxyl radical.<sup>[21]</sup> Consequently, after the nitric oxide source has been depleted re-initiation occurs from the slow breakdown of the LOONO adduct. Goss et al.<sup>[21]</sup> demonstrated that the sigmoidal dependence could be left-shifted by increasing the original peroxide content of the LDL. In addition maximal inhibition occurs at a rate of nitric oxide release that matches the rate of initiation.<sup>[44]</sup> Consequently a low, but continuous rate of nitric oxide formation is a more potent inhibitor of oxidation than a burst of nitric oxide release.

Nitric oxide will also inhibit lipid oxidation initiated by azo-initiators such as **ABAP.** This was first demonstrated in LDL where photoloysis of sodium nitroprusside was observed to inhibit LDL oxidation.<sup>[45]</sup> Recently O'Donnell et al.<sup>[46]</sup> demonstrated, using azo-initiators, that two nitric oxide molecules are consumed per chain reaction terminated. This stoichiometry suggests that the primary product **of** the reaction between nitric oxide and lipid is unstable and breaks down to a product that can also be scavenged by nitric oxide.

## **CONSEQUENCES FOR VASCULAR PATHOLOGIES**

Oxidative stress and free radical formation is a feature of many cardiovascular pathologies. The elevation of vascular superoxide formation has been linked to hypertension<sup>[47]</sup> and atherosclerosis.<sup>[12]</sup> The mechanisms for such elevation have been associated with many atherosclerotic risk factors such as diabetes,<sup>[48]</sup> hyperhomocystienemia,<sup>[49]</sup> and hypercholesterolemia.<sup>[12,47,50,51]</sup> In addition, nitric oxide has been shown to be a potent antiatherogenic agent that suppresses many elements of the atherosclerotic processes.<sup>[52]</sup> Such observations have led to the hypothesis that alteration of the balance between nitric oxide and superoxide generation by vascular cells may contribute to atherogenesis.<sup>[52-54]</sup>

This hypothesis may be particularly relevant to the biological oxidative modification of LDL. **As**  reviewed here, nitric oxide is a potent inhibitor of LDL oxidation. The low continuous flux of nitric oxide generated by the vascular endothelium would be expected to suppress such reaction in vivo. Only after removal of this antioxidant is sub-endothelial LDL oxidation likely to occur. In support of this are the observations that



**SCHEME 3** In the absence of superoxide, nitric oxide will inhibit lipid oxidation. In the presence of superoxide, nitric oxide will be scavenged to form peroxynitrite, which will initiate lipid oxidation. The balance between the levels **of**  nitric oxide and superoxide becomes a critical determinant of whether nitric oxide exhibits pro-oxidant or anti-oxidant behavior.

L-nitroarginine methyl ester, an inhibitor **of**  NOS, accelerates the atherosclerotic process in animal models. The diffusion limited reaction between nitric oxide and superoxide removes the antioxidant activity of nitric oxide and generates the potent LDL oxidant, peroxynitrite (Scheme **3).**  The formation of peroxynitrite usually results in protein tyrosyl residue nitration. It is of interest to note that nitrotyrosine has been observed in atherosclerotic lesions<sup>[55,56]</sup> and peroxynitrite has been implicated in the pathology **of** atherosclerosis.<sup>[57]</sup>

#### *Acknowledgment*

This work was supported by National Institutes of Health Grants **RR01008** and HL47250 (to B. K.) and GM55792 (to N. H.).

#### *References*

- 111 H. Esterbauer, J. Gebicki, H. Puhl and *G.* Jurgens **(1992).**  The role of lipid peroxidation and antioxidants in oxidative modification **of** LDL. *Free Radical Biology b Medicine,* **13,341-90.**
- **[21 E.** Niki **and** N. Noguchi **(1997).** Dynamics of oxidation of LDL and its inhibition by antioxidants. *Biofactors,* **6,201-8.**
- **I31** V. J. WLeary, L. Tilling, G. Fleetwood, D. Stone and **V.** Darley-Usmar **(1996).** The resistance **of** low-density lipoprotein to oxidation promoted by copper and its use as an index **of** antioxidant therapy. *Atherosclerosis,*  **119,169-79.**
- **141** V. W. Bowry, K. U. Ingold and R. Stocker **(1992).** VitaminE in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. *Biochemical Journal,*  **288,3414.**
- **[5]** D. Steinberg, **S.** Parthasarathy, **T.** E. Carew, J. C. Khoo and J. **L.** Witztum (1989). Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *New England Journal of Medicine, 320, 915-24.*
- **[6]** *S* Parthasarathy, D. Steinberg and J. L. Witztum **(1992).**  The role **of** oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. *Annual* **Review** of *Medicine,* **43,219-25.**
- *[7]* C. Yang, Z. W. Gu, M. Yang and **A.** M. Gotto Jr. **(1994).**  Primary structure **of** apoB-100. *Chemistry b Physics* of *Lipids,* **67-68,99-104.**
- *[S] S.* Parthasarathy and J. Bamett **(1990).** Phospholipase *A2*  activity of low density lipoprotein: evidence **for** an intrinsic phospholipase *A2* activity **of** apoprotein **B-100.**  *Proceedings* of *the National Academy* of *Sciences* of *the United States* of *America,* **87,9741-5.**
- **[9] A.** J. Cayatte, J. J. Palacino, K Horten **and** R. **A.** Cohen **(1994).** Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. *Artetiosclerosis b Thrombosis,* **14,753-9.**

RIGHTS LINK()

- **[lo]** K. Naruse, K. Shimizu, M. Muramatsu, Y. Toki, **Y.**  Miyazaki, K. Okumura, H. Hashimoto and T. Ito **(1994).**  Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. *Arteriosclerosis B Thrombosis,*  **14, 746–52.**
- [ll] R. C. Candipan, B. Y. Wang, R. Buitrago, P. S. Tsao and J. P. Cooke **(1996).** Regression or progression. Dependency on vascular nitric oxide. *Arteriosclerosis, Thrombosis 8 Vascular Biology,* **16(1), 44-50.**
- **[12]** R. L. Minor Jr., P. R. Myers, R. Guerra Jr., J. N. Bates and D. G. Harrison **(1990).** Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. *Journal* of *Clinical Investigation,* **86,2109-16.**
- **[13]** J. S. Beckman, T. W. Beckman, J. Chen, **I?** A. Marshall and B. **A.** Freeman **(1990).** Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proceedings* of *the National Academy* of *Sciences* of *the United States* of *America,*  **87,1620-4.**
- **[14]** G. L. Squadrito and W. A. Pryor **(1995).** The formation of peroxynitrite *in vivo* from nitric oxide and superoxide. *Chemico-Biological Interactions,* **96,203-6.**
- **[15]** Y. Ohara, T. E. Peterson and D. G. Harrison **(1993).**  Hypercholesterolemia increases endothelial superoxide anion production. *Journal of Clinical Investigation*, 91, **2546-51.**
- **[161** R. E. Huie and S. Padmaja **(1993).** The reaction of NO with superoxide. *Free Radical Research Communications,*  **18,195-9.**
- **[171** J. M. Wang, S. N. Chow and J. K. Lin **(1994).** Oxidation of LDL by nitric oxide and its modihcation by superoxides in macrophage and cell-free systems. *FEBS Letters,* **342, 171-5.**
- [IS] G. J. Chang, P. Woo, H. M. Honda, L. J. Ignarro, L. Young, J. **A.** Berliner and L. L. Demer **(1994).** Oxidation of LDL to a biologically active form by derivatives of nitric oxide and nitrite in the absence of superoxide. Dependence on pH and oxygen. *Arteriosclerosis B Thrombosis,* **14, 1808-14.**
- **[191** V. M. Darley-Usmar, N. Hogg, **V.** J. OLeary, M. T. Wilson and S. Moncada **(1992).** The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low-density lipoprotein. *Free Radical Research*  Communications, 17, 9-20.
- [201 W. Jessup, D. Mohr, S. P. Gieseg, R. T. Dean and R. Stocker **(1992).** The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. *Biochimica et Biophysicu Acta,*  **1180**, 73-82.
- **[211** S. **P.** Goss, N. Hogg and B. Kalyanaraman **(1995)**  The antioxidant effect of spermine NONOate in human low-density lipoprotein. *Chemical Research in Toxicology,*  8,800-6.
- [221 **A.** A. Gallon and W. A. Pryor **(1994).** The reaction of low levels of nitrogen dioxide with methyl linoleate in the presence and absence of oxygen. *Lipids,* **29,171-6.**
- **1231** N. V. Gorbunov, A. N. Osipov,M. A. Sweetland, B. W. Day, N. M. Elsayed and V. E. Kagan **(1996).** NO-redox paradox: direct oxidation of alpha-tocopherol and alphatocopherol-mediated oxidation of ascorbate. *Biochemical and Biophysical Research Communications,* **219, 83541.**
- **1241** N. Hogg, R. J. Singh, S. **P.** Goss and B. Kalyanaraman **(1996).** The reaction between nitric oxide and alpha-

tocopherol: a reappraisal. *Biochemical* **6** *Biophysical Research Communications, 224, 696-702.* 

- **1251** I. Gabr, R. P. Patel, M. C. R. Symons and M. T. Wilson **(1995).** Novel reactions of nitric oxide in biological systems. *Journal* of *the Chemical Society, Chemical Communications,* **915-6.**
- **[26]** M. Feelisch, J. Ostrowski and E. Noack **(1989).** On the mechanism of NO release from sydnonimines. *Journul* of *Cardiovascular Pharmacology,* **14** (Suppl. **ll),** SlX22.
- **[27]** N. Hogg, **V.** M. Darley-Usmar, M. T. Wilson and *S.*  Moncada **(1992).** Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. *Biochemical Journal,* **281,419-24.**
- **[28]** A. Graham, N. Hogg, B. Kalyanaraman, V. OLeary, V. Darley-Usmar and S. Moncada **(1993).** Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. *FEBS Letters,*  **330,181-5.**
- **[29]** N. Hogg, **V.** M. Darley-Usmar, M. T. Wilson and S. Moncada **(1993).** The oxidation of alpha-tocopherol in human low-density lipoprotein by the simultaneous generation **of** superoxide and nitric oxide. *FEBS Lefters,*  **326,199-203.**
- **1301** H. de Groot, U. Hegi and H. Sies **(1993)** Loss of alphatocopherol upon exposure to nitric oxide or the sydnonimine **SIN-1**. *FEBS Letters*, 315, 139-42.
- **[31]** N. Hogg, J. Joseph and B. Kalyanaraman **(1994).** The oxidation **of** alpha-tocopherol and trolox by peroxynitrite. *Archives* of *Biochemistry B Biophysics,* **314,153-8.**
- **[32]** N. C. Hoglen, S. C. Waller, I. G. Sipes and D. C. Liebler (1997). Reactions of peroxynitrite with  $\gamma$ -tocopherol. *Chemical Research in Toxicology,* **10,401-7.**
- **1331** S. Christen, A. A. Woodall, M. K. Shigenaga, P. T. Southwell-Keely, M. **W.** Duncan and B. N. Ames **(1997).**   $\gamma$ -Tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol physiological implications. *Proceedings* of *the National Academy* of *Sciences* of *the United States* of *America,* **94, 3217-22.**
- **1341** E. Ferguson, R. J. Singh, N. Hogg and B. Kalyanaraman **(1997).** The mechanism of apolipoprotein B-100 thiol depletion during oxidative modification of low-density lipoprotein. *Archives* of *Biochemistry 8 Biophysics,* **341, 287-94.**
- **[351** M. T. Yates, L. E. Lambert, J. P. Whitten, I. McDonald, M. Mano, G. Ku and S. J. Mao **(1992).** A protective role for nitric oxide in the oxidative modification of low-density lipoproteins by mouse macrophages. *FEBS Letters,* **309, 135-8.**
- **1361** J. B. Hibbs Jr. **(1991).** Synthesis of nitric oxide from Larginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. *Research in Immunology,* **142,565-9.**
- **I371** H. Esterbauer, G. Striegl, H. Puhl and M. Rotheneder **(1989).** Continuous monitoring of *in vitro* oxidation of human low-density lipoprotein. *Free Radical Research Communications,* **6,67-75.**
- **1381** H. Esterbauer, M. Dieber-Rotheneder, G. Waeg, G. Striegl and G. Jurgens (1990). Biochemical, structural, and functional properties **of** oxidized low-density lipoprotein. *Chemical Research in Toxicology,* **3, 77-92.**
- **1391** V. J. OLeary, L. Tilling, G. Fleetwood, D. Stone and V. Darley-Usmar **(1996).** The resistance of low-density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy. *Atherosclerosis,* **119, 169-79.**

RIGHTSLINK()

- **I401** K. Sato, E. Niki and H. Shimasaki **(1990).** Free radicalmediated chain oxidation of low-density lipoprotein and its synergistic inhibition by vitamin E and vitamin C. *Archives* of *Biochemist y* **6** *Biophysics,* **279,402-5.**
- **[41]** G. W. Burton and K. U. Ingold **(1981).** Autoxidation of biological molecules **1.** The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants *in vitro. Journal* of *the American Chemical Society,* **103, 6472-7.**
- **[42] S.** Padmaja and R. E. Huie **(1993).** The reaction **of** nitric oxide with organic peroxyl radicals. *Biochemical b Biophysical Research Communications,* **195,53944.**
- **[43] H.** Rubbo, **S.** Parthasarathy Barnes, **S.** M. Kirk, B. Kalyanaraman and 8. A. Freeman **(1995).** Nitric oxide inhibition of lipoxygenase-dependent liposome and lowdensity lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogencontaining oxidized lipid derivatives. *Archives* of *Biochemistry b Biophysics,* **324,1525.**
- *[MI S.* F'. Goss, N. Hogg and 8. Kalyanaraman **(1997).** The effect of nitric oxide release rates on the oxidation of human low-density lipoprotein. *Journal* of *Biological Chemistry,* **272,21647-53.**
- **[45]** N. **Hogg,** B. Kalyanaraman, J. Joseph, A. Struck and S. Parthasarathy **(1993).** Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. *FEBS Letters,* **334,17C-4.**
- *[46]* V. B. O'Donnell, P. H. Chumley,N. Hogg, **A.** Bloodsworth, V. Darley-Usmar and 8. **A.** Freeman **(1997).** Nitric oxide inhibition of lipid peroxidation: Kinetics of reaction with lipid peroxyl radicals and comparison with  $\alpha$ -tocopherol. *Biochemistry* (in press).
- **[47l** T. Munzel, T. Heitzer and D. G. Harrison **(1997).** The physiology and pathophysiology of the nitric oxide/ superoxide system. *Herz.,* **22,158-72.**
- **[48]** J. C. Monboisse, P. Gillery, **F.** X. Maquart and J. P. Bore1 **(1990).** Production of superoxide anion by glycated proteins: involvement in complications of diabetes mellitus. *Advances in Experimental Medicine 6* Biology, **264,5514**
- [49] A. J. Olszewski and K. S. McCuIly (1993). Homocysteine metabolism and the oxidative modification of proteins and lipids. *Free Radical Biology* **6** *Medicine,* **14,683-93.**
- **[SO]** K. A. Pritchard Jr., L. Groszek, D. M. Smalley, **W.** C. Sessa, M. Wu, P. Villalon, M. S. Wolin and M. B. Stemerman **(1995).** Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. *Circulation Research,* **77,510-8.**
- **1511** C. R. White, V. Darley-Usmar, W. R. Berrington, M. McAdams, J. Z. Gore, J. **A.** Thompson, D. A. Parks, M. M. Tarpey and **B.** A. Freeman **(19%).** Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. *Proceedings* of *the National Academy* of *Sciences* of *the United States* of *Amm'ca,*  **93,8745-9.**
- **[52]** J. **P.** Cooke and P S. Tsao **(1994).** Is NO an endogenous antiatherogenic molecule? *Arteriosclerosis* **6** *Thrombosis,*  **14,653-5.**
- **[53]** N. Hogg **(1995).** Pro-oxidant and antioxidant effects of nitric oxide. In "Analysis of Free Radicals in Biological Systems". Favier, Cadet, Kalyanaraman, Fontecave and Pierre (Eds.), Birkhauser Verlag, Boston.
- **[54] V.** Darley-Usmar and B. **Halliwell(1996). Blood** radicals: reactive nitrogen species, reactive oxygen **species,** transition metal ions, and the vascular system. *Pharmaceutical Research,* **13,649-62.**
- **1551** J. **S.** Beckman, **Y.** Z. Ye, **P.** G. Anderson, J. Chen, M. **A.**  Accavitti, M. M. Tarpey and C. R. White **(1994).** Extensive nitration of protein tyrosines in human atherosclerosis dated by immunohistochemistry *Biological Chemistry*  Hoppe-Sylers', 375, 81-88.
- [56] C. Leeuwenburgh, M. M. Hardy, S. L. Hazen, P. Wagner, S. Oh-ishi, U. P. Steinbrecher and J. W. Heinecke (1997). Reactive nitrogen intermediates promote low-density lipoprotein oxidation in human atherosclerotic intima. *Journal* **of** *Biological Chemistry,* **272(3), 1433-6.**
- **[57]** C. R. White, T. A. Brock, L. Y. Chang, J. Crapo, **P. Briscoe,**  D. Ku, W. **A.** Bradley, **S.** H. Gianiurco, J. **Gore,** 8. **A.**  Freeman and M. M. Tarpey **(1994).** Superoxide and peroxynitrite in atherosclerosis. Proceedings of the *National Academy* of *Sciences* of *the United States* of *America,*  **91.1044-48.**

RIGHTSLINKO